Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
2019
Abstract Background Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
416
Citations
NaN
KQI